Survival outcomes by TP53 mutation status in metastatic breast cancer

Funda Meric-Bernstam, Xiaofeng Zheng, Maryam Shariati, Senthil Damodaran, Chetna Wathoo, Lauren Brusco, Mehmet Esat Demirhan, Coya Tapia, Agda Karina Eterovic, Reva K. Basho, Naoto T. Ueno, Filip Janku, Aysegul Sahin, Jordi Rodon, Russell Broaddus, Tae Beom Kim, John Mendelsohn, Kenna R.Mills Shaw, Debu Tripathy, Gordon B. MillsKen Chen

    Research output: Contribution to journalArticle

    3 Scopus citations

    Abstract

    Purpose To determine the significant genomic alterations in patients with metastatic breast cancer (MBC) and survival outcomes in common genotypes. Patients and Methods High-depth next-generation sequencing was performed for 202 genes in tumor and normal DNA from 257 patients with MBC, including 165 with estrogen receptor/progesterone receptor-positive and human epidermal growth factor receptor 2 (HER2 [hormone receptor positive (HR+)])-positive, 32 with HER2-positive, and 60 with triple-negative (estrogen receptor/progesterone receptor-negative and HER2-negative) disease. Kaplan-Meier survival analysis was performed in the discovery set, in patients with breast cancer analyzed in The Cancer Genome Atlas, and in a separate cohort of 98 patients with MBC who underwent clinical genomic testing. Results Significantly mutated genes (SMGs) varied by histology and tumor subtype, but TP53 was an SMG in all three subtypes. The most SMGs in patients with HR+ cancer were PIK3CA (32%), TP53 (29%), GATA3 (15%), CDH1 (8%), MAP3K1 (8%), PTEN (5%), TGFBR2 (4%), AKT1 (4%), and MAP2K4 (4%). TP53 mutations were associated with shorter recurrence-free survival (P =.004), progression-free survival (P <.001), and overall survival (P =.003). Furthermore, TP53 status was prognostic among patients with HR+ cancer with PIK3CA mutations. TP53 mutations were associated with poorer overall survival in the 442 patients with HR+ breast cancer analyzed in The Cancer Genome Atlas (P =.042) and in an independent set of 96 patients with HR+ MBC who underwent clinical sequencing (P <.001). Conclusion SMGs differ by tumor subtype, but TP53 is significantly mutated in all three breast cancer subtypes. TP53 mutations are associated with poor prognosis in HR+ breast cancer and should be considered in the design and interpretation of precision oncology trials.

    Original languageEnglish (US)
    JournalJCO Precision Oncology
    Volume2
    DOIs
    StatePublished - Jan 1 2018

    ASJC Scopus subject areas

    • Cancer Research
    • Oncology

    Fingerprint Dive into the research topics of 'Survival outcomes by TP53 mutation status in metastatic breast cancer'. Together they form a unique fingerprint.

  • Cite this

    Meric-Bernstam, F., Zheng, X., Shariati, M., Damodaran, S., Wathoo, C., Brusco, L., Demirhan, M. E., Tapia, C., Eterovic, A. K., Basho, R. K., Ueno, N. T., Janku, F., Sahin, A., Rodon, J., Broaddus, R., Kim, T. B., Mendelsohn, J., Shaw, K. R. M., Tripathy, D., ... Chen, K. (2018). Survival outcomes by TP53 mutation status in metastatic breast cancer. JCO Precision Oncology, 2. https://doi.org/10.1200/PO.17.00245